Data / Companies / BLLN
BillionToOne, Inc.Nasdaq
BLLN-US · CIK 0002070849 · Services-Medical Laboratories
Revenue by quarter
US$ · last 8| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $109.4M | $8.1M | 0.15 |
| Q1 FY2026 | $108.4M | $18.0M | 0.34 |
| Q4 FY2025 | $96.1M | $6.0M | 0.45 |
| Q3 FY2025 | $83.5M | $5.7M | 0.10 |
Newest filings
All 27| Form | Filed | |
|---|---|---|
| 10-Q | 5 Aug 2026 | |
| 8-K | 5 Aug 2026 | |
| 8-K | 29 Jun 2026 | |
| 8-K | 16 Jun 2026 | |
| 10-Q | 6 May 2026 | |
| 8-K | 6 May 2026 | |
| ARS | 21 Apr 2026 | |
| DEFA14A | 21 Apr 2026 |
Description
- Ticker
- BLLN-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Services-Medical Laboratories
- SIC division
- Services
- CIK
- 0002070849
- Fiscal year ends
- Dec
- Filings held
- 27 since 2025
- 8-K events
- 8
- Shares short
- 2.9M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
| Fiscal period | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Period ending | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K |
| Report filed | 11 Mar 2026† | 11 Mar 2026† | 11 Mar 2026 |
| Revenue | 72M | 153M | 305M |
| Cost of revenue | 54M | 72M | 97M |
| Gross profit | 17M | 81M | 208M |
| Gross margin | 24.1% | 53.0% | 68.3% |
| Research and development | 22M | 37M | 49M |
| Selling, general and administrative | 64M | 91M | 143M |
| Operating income | -69M | -47M | 16M |
| Operating margin | -96.9% | -30.9% | 5.3% |
| Profit before tax | -83M | -42M | 8M |
| Income tax | 0M | 0M | 0M |
| Tax rate | – | – | 3.9% |
| Net income | -83M | -42M | 7M |
| Net margin | -115.3% | -27.2% | 2.4% |
| Earnings per share, diluted | -8.45 | -4.12 | 0.14 |
| Diluted shares | 10M | 10M | 21M |
† Reported in a later filing that carries this period again, as a comparative or restated figure. The period's own original filing may show different numbers.
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
- Market cap
- $5.3B
- Price
- $113.21
- Stock P/E
- 129.90×
- Price to book
- 9.95×
- Enterprise value
- $4.9B
- EV / EBITDA
- 97.24×
- Market cap / sales
- 13.44×
- 52-week high
- $149.97
- 52-week low
- $64.03
- Gross margin, TTM
- 71.3%
- Operating margin
- 10.9%
- Net margin
- 9.5%
- FCF margin
- 8.3%
- ROE
- 7.0%
- ROCE
- 6.9%
- Cash conversion
- 1.20×
- Interest cover
- 1056.15×
- Effective tax rate, TTM
- 0.5%
- Cash and equivalents
- $548.6M
- Borrowings
- $91.0M
- Net debt
- -$457.6M
- Debt to equity
- 0.17×
- Shareholders' equity
- $536.8M
- Total assets
- $729.7M
- Shares outstanding
- 47,187,038
- Share count, last 12 months
- 346.8%
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
- Prenatal$277.1M 90.8%
- Oncology$25.0M 8.2%
- Clinical trial support and other services$3.1M 1.0%
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 | |
| 29 Jun 2026 | 8-K | Material agreementNew debt | 1.01, 2.03, 9.01 | |
| 16 Jun 2026 | 8-K | Material agreementNew debt | 1.01, 2.03, 9.01 | |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 | |
| 4 Mar 2026 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 12 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01 | |
| 9 Dec 2025 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 10 Nov 2025 | 8-K | Bylaws or fiscal year changeOther events | 5.03, 8.01, 9.01 |
Every filing
The company's filings with the SEC, newest first: 27 held. Insider, fund and large-holder filings have their own tables below.
| 5 Aug 2026 | 10-Q | 30 Jun 2026 | |
| 5 Aug 2026 | 8-K | 5 Aug 2026 | |
| 29 Jun 2026 | 8-K | 23 Jun 2026 | |
| 16 Jun 2026 | 8-K | 10 Jun 2026 | |
| 6 May 2026 | 10-Q | 31 Mar 2026 | |
| 6 May 2026 | 8-K | 6 May 2026 | |
| 21 Apr 2026 | ARS | 31 Dec 2025 | |
| 21 Apr 2026 | DEFA14A | – | |
| 21 Apr 2026 | DEF 14A | 10 Jun 2026 | |
| 11 Mar 2026 | 10-K | 31 Dec 2025 | |
| 4 Mar 2026 | 8-K | 4 Mar 2026 | |
| 12 Jan 2026 | 8-K | 12 Jan 2026 | |
| 10 Dec 2025 | 10-Q | 30 Sep 2025 | |
| 9 Dec 2025 | 8-K | 9 Dec 2025 | |
| 10 Nov 2025 | 8-K | 7 Nov 2025 | |
| 6 Nov 2025 | S-8 | – | |
| 5 Nov 2025 | CERT | – | |
| 3 Nov 2025 | 8-A12B | – | |
| 17 Oct 2025 | S-1/A | – | |
| 7 Oct 2025 | S-1 | – | |
| 17 Sep 2025 | DRSLTR | – | |
| 17 Sep 2025 | DRS/A | – | |
| 26 Aug 2025 | UPLOAD | – | |
| 11 Aug 2025 | DRSLTR | – | |
| 11 Aug 2025 | DRS/A | – | |
| 17 Jul 2025 | UPLOAD | – | |
| 20 Jun 2025 | DRS | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 28 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 8,333 | $118.00 | $983.3K | 0 | 30 Oct 2026 |
| 28 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,667 | $118.00 | $314.7K | 146,501 | 30 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 900 | $98.43 | $88.6K | 4,250 | 16 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,861 | $99.84 | $185.8K | 2,389 | 16 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,276 | $100.60 | $128.4K | 1,113 | 16 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 980 | $101.79 | $99.8K | 133 | 16 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 133 | $102.78 | $13.7K | 0 | 16 Oct 2026 |
| 14 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 3,083 | $98.32 | $303.1K | 100 | 16 Oct 2026 |
| 14 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 100 | $99.00 | $9.9K | 0 | 16 Oct 2026 |
| 14 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,667 | $98.00 | $261.4K | 149,168 | 16 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,961 | $91.57 | $179.6K | 14,706 | 14 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,553 | $93.05 | $237.5K | 12,153 | 14 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 6,763 | $93.65 | $633.3K | 5,390 | 14 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 3,869 | $94.61 | $366.1K | 1,521 | 14 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,521 | $96.39 | $146.6K | 0 | 14 Oct 2026 |
| 12 Oct 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,667 | $97.61 | $260.3K | 151,835 | 14 Oct 2026 |
| 5 Oct 2026 | Ten Bosch John RoderickSVP of Laboratory Operations | Sale under a trading plan | 1,417 | $105.15 | $149.0K | 19,385 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 866 | $105.90 | $91.7K | 20,134 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 1,909 | $107.19 | $204.6K | 18,225 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 4,284 | $108.39 | $464.4K | 13,941 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 2,921 | $109.00 | $318.4K | 11,020 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 20 | $110.08 | $2.2K | 11,000 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 555 | $105.56 | $58.6K | 10,445 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 400 | $106.10 | $42.4K | 10,045 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 2,200 | $107.47 | $236.4K | 7,845 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 4,916 | $108.53 | $533.6K | 2,929 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 1,829 | $109.14 | $199.6K | 1,100 | 7 Oct 2026 |
| 5 Oct 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 100 | $110.09 | $11.0K | 1,000 | 7 Oct 2026 |
| 28 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 8,333 | $120.64 | $1.0M | 0 | 30 Sep 2026 |
| 28 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,666 | $120.64 | $321.6K | 154,502 | 30 Sep 2026 |
| 24 Sep 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 3,333 | $125.00 | $416.6K | 1,000 | 28 Sep 2026 |
| 24 Sep 2026 | Ten Bosch John RoderickSVP of Laboratory Operations | Sale under a trading plan | 1,416 | $120.00 | $169.9K | 22,219 | 28 Sep 2026 |
| 21 Sep 2026 | Ten Bosch John RoderickSVP of Laboratory Operations | Sale under a trading plan | 1,416 | $106.61 | $151.0K | 23,635 | 23 Sep 2026 |
| 17 Sep 2026 | Lynch Thomas P.See Remarks | Sale under a trading plan | 19,384 | $110.36 | $2.1M | 16,428 | 21 Sep 2026 |
| 17 Sep 2026 | Lynch Thomas P.See Remarks | Sale under a trading plan | 6,968 | $110.30 | $768.6K | 9,460 | 21 Sep 2026 |
| 17 Sep 2026 | Lynch Thomas P.See Remarks | Sale under a trading plan | 2,920 | $110.31 | $322.1K | 6,540 | 21 Sep 2026 |
| 17 Sep 2026 | Lynch Thomas P.See Remarks | Sale under a trading plan | 5,840 | $110.29 | $644.1K | 700 | 21 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 4,465 | $98.63 | $440.4K | 20,534 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,456 | $99.57 | $244.5K | 18,078 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,531 | $100.58 | $254.6K | 15,547 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 7,214 | $101.44 | $731.8K | 8,333 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,680 | $98.64 | $165.7K | 6,653 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 1,500 | $99.57 | $149.4K | 5,153 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,010 | $100.78 | $202.6K | 3,143 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 3,143 | $101.49 | $319.0K | 0 | 16 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanChairman and CEO | Sale under a trading plan | 2,666 | $98.00 | $261.3K | 157,168 | 16 Sep 2026 |
| 9 Sep 2026 | Ten Bosch John RoderickSVP of Laboratory Operations | Sale under a trading plan | 1,416 | $97.54 | $138.1K | 25,051 | 11 Sep 2026 |
| 9 Sep 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 10,000 | $97.54 | $975.4K | 11,000 | 11 Sep 2026 |
| 9 Sep 2026 | Tsao DavidChief Technology Officer | Sale under a trading plan | 10,000 | $100.00 | $1.0M | 1,000 | 11 Sep 2026 |
| 8 Sep 2026 | Lynch Thomas P.See Remarks | Sale under a trading plan | 38 | $96.47 | $3.7K | 20,662 | 10 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 28 Oct 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 2,667 | $314.7K | 28 Oct 2026 |
| 28 Oct 2026 | Atay OguzhanOfficer, Director | 8,333 | $983.3K | 28 Oct 2026 |
| 15 Oct 2026 | Atay OguzhanOfficer, Director | 5,150 | $516.2K | 15 Oct 2026 |
| 14 Oct 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 2,667 | $261.4K | 14 Oct 2026 |
| 14 Oct 2026 | Atay OguzhanOfficer, Director | 3,183 | $313.0K | 14 Oct 2026 |
| 13 Oct 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 2,667 | $260.3K | 12 Oct 2026 |
| 13 Oct 2026 | Atay OguzhanOfficer, Director | 16,667 | $1.6M | 12 Oct 2026 |
| 5 Oct 2026 | Tsao DavidOfficer, Director | 1,750 | $184.0K | 5 Oct 2026 |
| 5 Oct 2026 | ten Bosch John RoderickOfficer | 2,834 | $298.0K | 5 Oct 2026 |
| 5 Oct 2026 | Tsao DavidOfficer, Director | 20,000 | $2.2M | 5 Oct 2026 |
| 28 Sep 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 2,666 | $321.6K | 28 Sep 2026 |
| 28 Sep 2026 | Atay OguzhanOfficer, Director | 8,333 | $1.0M | 28 Sep 2026 |
| 24 Sep 2026 | ten Bosch John RoderickOfficer | 1,416 | $169.9K | 24 Sep 2026 |
| 24 Sep 2026 | Tsao DavidOfficer, Director | 3,333 | $416.6K | 24 Sep 2026 |
| 21 Sep 2026 | ten Bosch John RoderickOfficer | 1,416 | $151.0K | 21 Sep 2026 |
| 17 Sep 2026 | Lynch Thomas P.Officer | 35,112 | $3.9M | 17 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 5,332 | $522.5K | 14 Sep 2026 |
| 14 Sep 2026 | Atay OguzhanOfficer, Director | 24,999 | $2.5M | 14 Sep 2026 |
| 9 Sep 2026 | ten Bosch John RoderickOfficer | 1,416 | $138.1K | 9 Sep 2026 |
| 9 Sep 2026 | Tsao DavidOfficer, Director | 1,750 | $170.7K | 9 Sep 2026 |
| 9 Sep 2026 | Tsao DavidOfficer, Director | 20,000 | $2.0M | 9 Sep 2026 |
| 8 Sep 2026 | Lynch Thomas P.Officer | 20,000 | $2.0M | 8 Sep 2026 |
| 25 Aug 2026 | ten Bosch John RoderickOfficer | 1,417 | $141.7K | 25 Aug 2026 |
| 25 Aug 2026 | Tsao DavidOfficer, Director | 10,000 | $1.0M | 25 Aug 2026 |
| 10 Aug 2026 | ten Bosch John RoderickOfficer | 1,417 | $131.6K | 10 Aug 2026 |
| 10 Aug 2026 | Tsao DavidOfficer, Director | 3,500 | $325.0K | 10 Aug 2026 |
| 10 Aug 2026 | Tsao DavidOfficer, Director | 10,000 | $928.6K | 10 Aug 2026 |
| 5 Aug 2026 | Atay OguzhanOfficer, Director | 15,539 | $2.3M | 5 Aug 2026 |
| 3 Aug 2026 | Atay OguzhanOfficer, Director | 2,500 | $343.4K | 3 Aug 2026 |
| 3 Aug 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 12,500 | $1.7M | 3 Aug 2026 |
| 3 Aug 2026 | Atay OguzhanOfficer, Director | 32,500 | $4.5M | 3 Aug 2026 |
| 31 Jul 2026 | Sakakibara Shan RikuOfficer | 4,000 | $560.8K | 31 Jul 2026 |
| 16 Jul 2026 | Johnson Nancy JoAnnOfficer | 14,199 | $1.8M | 16 Jul 2026 |
| 13 Jul 2026 | Tsao DavidOfficer, Director | 20,000 | $250.5K | 13 Jul 2026 |
| 13 Jul 2026 | Tsao DavidOfficer, Director | 3,500 | $439.1K | 13 Jul 2026 |
| 13 Jul 2026 | ten Bosch John RoderickOfficer | 4,251 | $533.3K | 13 Jul 2026 |
| 9 Jul 2026 | Sakakibara Shan RikuOfficer | 8,000 | $1.0M | 9 Jul 2026 |
| 9 Jul 2026 | Atay OguzhanOfficer, Director | 12,500 | $1.6M | 9 Jul 2026 |
| 6 Jul 2026 | Atay OguzhanOfficer, Director | 2,500 | $300.0K | 6 Jul 2026 |
| 6 Jul 2026 | Atay OguzhanMember of immediate family of any of the foregoing | 12,500 | $1.5M | 6 Jul 2026 |
| 6 Jul 2026 | Atay OguzhanOfficer, Director | 26,250 | $3.1M | 6 Jul 2026 |
| 1 Jul 2026 | Johnson Nancy JoAnnOfficer | 801 | $100.1K | 1 Jul 2026 |
| 29 Jun 2026 | ten Bosch John RoderickOfficer | 1,416 | $169.9K | 29 Jun 2026 |
| 24 Jun 2026 | Sakakibara Shan RikuOfficer | 8,000 | $880.0K | 24 Jun 2026 |
| 15 Jun 2026 | ten Bosch John RoderickOfficer | 2,832 | $287.4K | 15 Jun 2026 |
| 15 Jun 2026 | Tsao DavidOfficer, Director | 3,500 | $355.1K | 15 Jun 2026 |
| 15 Jun 2026 | Tsao DavidOfficer, Director | 20,000 | $2.0M | 15 Jun 2026 |
| 9 Jun 2026 | Johnson Nancy JoAnnOfficer | 10,582 | $1.1M | 9 Jun 2026 |
| 8 Jun 2026 | Atay OguzhanOfficer, Director | 2,500 | $245.6K | 8 Jun 2026 |
| 8 Jun 2026 | Johnson Nancy JoAnnOfficer | 3,418 | $339.3K | 8 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 17 Feb 2026 | David Tsao | 13G | 6.9% | 3.0M |
| 17 Feb 2026 | Oguzhan Atay | 13G | 7.3% | 3.2M |
| 13 Feb 2026 | NeoTribe Ventures I, L.P. ("NTV I") | 13G | 10.6% | 4.4M |
| 20 Jan 2026 | Hummingbird Ventures Management NV | 13D | 19.6% | 7.9M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
| 15 Oct 2026 | 2.9M | +4.04% | 5.53 |
| 30 Sep 2026 | 2.8M | +7.34% | 3.88 |
| 15 Sep 2026 | 2.6M | +11.79% | 4.84 |
| 31 Aug 2026 | 2.3M | +20.49% | 4.17 |
| 14 Aug 2026 | 1.9M | +1.49% | 1.8 |
| 31 Jul 2026 | 1.9M | -20.21% | 3.38 |
| 15 Jul 2026 | 2.4M | -0.71% | 3.58 |
| 30 Jun 2026 | 2.4M | +34.2% | 2.96 |
| 15 Jun 2026 | 1.8M | +7.41% | 2.18 |
| 29 May 2026 | 1.7M | +14.77% | 2.82 |
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
166
quarter to 30 Jun 2026
Added or new
125
since 31 Mar 2026
Trimmed
13
in the quarter
Largest holder
Adams Street Partners LLC
$205.3M
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| BillionToOne, Inc.this company | $5.3B | $397.4M | – | 10.9% | 9.5% | 7.0% | 129.9× | 97.2× |
| Natera, Inc. | $59.5B | $2.7B | 37.8% | -10.7% | -7.1% | -10.6% | – | – |
| Labcorp Holdings Inc. | $29.4B | $14.6B | 6.0% | 10.3% | 6.9% | 11.3% | 29.7× | 15.8× |
| Quest Diagnostics Inc. | $27.7B | $11.8B | 9.1% | 14.6% | 9.5% | 14.8% | 25.1× | 14.1× |
| Guardant Health, Inc. | $23.9B | $1.2B | 42.7% | -39.7% | -38.3% | – | – | – |
| Caris Life Sciences, Inc. | $9.7B | $989.6M | – | 15.5% | 10.6% | 17.8% | 95.3× | 54.0× |
| Grail, Inc. | $6.4B | $165.3M | 23.1% | -338.4% | -236.9% | -15.4% | – | – |
| RadNet, Inc. | $5.8B | $2.3B | 18.9% | 3.1% | -0.9% | -1.9% | – | 26.4× |
| CareDx, Inc. | $4.6B | $497.4M | 38.9% | 23.4% | 25.9% | 27.5% | 36.6× | 32.3× |
| Veracyte, Inc. | $4.0B | $561.9M | 17.3% | 18.8% | 20.4% | 8.2% | 35.5× | 29.4× |
| Fortrea Holdings Inc. | $2.1B | $2.7B | -3.4% | 0.5% | -2.6% | -12.9% | – | 31.6× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence